Analyst Activity – Cowen Reiterates Buy on Intra-Cellular Therapies (NASDAQ:ITCI)

ME Staff
-
0

Analyst Ratings For Intra-Cellular Therapies (NASDAQ:ITCI)

Today, Cowen reiterated its Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) with a price target of $28.00.

Some recent analyst ratings include

  • 3/2/2018-Cowen Reiterated Rating of Buy.
  • 3/1/2018-Cantor Fitzgerald Reiterated Rating of Buy.
  • 2/26/2018-JPMorgan Chase & Co. initiated coverage with a Overweight rating.
  • 2/8/2018-Royal Bank of Canada initiated coverage with a Outperform rating.
  • 12/15/2017-Canaccord Genuity initiated coverage with a Buy rating.
  • 11/8/2017-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
  • 9/8/2017-BTIG Research Reiterated Rating of Buy.

Recent Insider Trading Activity For Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI) has insider ownership of 19.80% and institutional ownership of 76.93%.

  • On 2/16/2018 Lawrence J Hineline, VP, sold 49,700 with an average share price of $20.02 per share and the total transaction amounting to $994,994.00.
  • On 1/22/2018 Michael Halstead, SVP, sold 25,500 with an average share price of $18.03 per share and the total transaction amounting to $459,765.00.
  • On 1/8/2018 Kimberly E Vanover, SVP, sold 772 with an average share price of $17.46 per share and the total transaction amounting to $13,479.12.
  • On 1/8/2018 Sharon Mates, Chairman, sold 6,604 with an average share price of $17.48 per share and the total transaction amounting to $115,437.92.
  • On 1/5/2018 Kimberly E Vanover, SVP, sold 1,185 with an average share price of $17.37 per share and the total transaction amounting to $20,583.45.
  • On 1/5/2018 Sharon Mates, Chairman, sold 11,257 with an average share price of $17.08 per share and the total transaction amounting to $192,269.56.
  • On 1/4/2018 Lawrence J Hineline, CFO, sold 3,192 with an average share price of $15.67 per share and the total transaction amounting to $50,018.64.

Recent Trading Activity for Intra-Cellular Therapies (NASDAQ:ITCI)
Shares of Intra-Cellular Therapies closed the previous trading session at 18.95 up +0.91 5.04% with shares trading hands.